Together, we are stronger.
Treatments for stage 0 breast cancer
The following are treatment options for stage 0 (non-invasive, or in situ) breast cancer. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.
Ductal carcinoma in situ (DCIS) is the most common type of non-invasive breast cancer. Lobular carcinoma in situ (LCIS) increases a woman’s risk for developing breast cancer, but it is not considered a cancer.
Surgery is the main treatment for DCIS. Most women are offered breast-conserving surgery. If there are several areas of DCIS in the breast, doctors may do a mastectomy to make sure that all of the cancer is removed. Doctors do not remove lymph nodes under the arm (called axillary lymph node dissection) for DCIS because this cancer has not spread outside the duct in the breast.
To lower their risk of developing invasive breast cancer, some women with LCIS may choose to have their breasts removed (called a prophylactic mastectomy).
External beam radiation therapy is usually given after breast-conserving surgery for DCIS. It is used to lower the risk that cancer will come back (recur) in the breast, especially if there is high-grade DCIS. In rare cases, radiation therapy isn’t needed because the DCIS is low grade, it is only in one very small area of the breast and it is completely removed with surgery.
LCIS is not treated with radiation therapy.
Tamoxifen (Nolvadex, Tamofen) is offered for hormone receptor–positive DCIS. Hormonal therapy is started as soon as the cancer is diagnosed. It is given for up to 10 years to lower the risk that you will develop another breast cancer.
Women with LCIS may be offered tamoxifen to lower the risk that an invasive breast cancer will develop.
Many clinical trials in Canada are open to women with breast cancer. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.
Cancer information in over a hundred languages
The Canadian Cancer Society’s Cancer Information Service (CIS) is Canada’s only national, bilingual, toll-free service that offers personalized comprehensive cancer information in over 100 languages.